365,833 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Purchased by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the fourth quarter, HoldingsChannel reports. The fund purchased 365,833 shares of the company’s stock, valued at approximately $8,126,000.

A number of other institutional investors also recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in Cellebrite DI in the fourth quarter worth about $9,995,000. Aigen Investment Management LP increased its stake in shares of Cellebrite DI by 16.9% during the fourth quarter. Aigen Investment Management LP now owns 52,595 shares of the company’s stock valued at $1,159,000 after purchasing an additional 7,598 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Cellebrite DI during the fourth quarter valued at approximately $234,000. Steward Partners Investment Advisory LLC increased its stake in shares of Cellebrite DI by 12.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after purchasing an additional 1,463 shares in the last quarter. Finally, Tower View Wealth Management LLC increased its stake in shares of Cellebrite DI by 1.3% during the fourth quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company’s stock valued at $2,915,000 after purchasing an additional 1,660 shares in the last quarter. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Stock Up 0.5 %

NASDAQ:CLBT opened at $17.57 on Monday. The company’s 50 day moving average price is $21.87 and its 200-day moving average price is $19.71. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -12.64, a PEG ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CLBT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Friday, February 14th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Lake Street Capital raised their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI has a consensus rating of “Buy” and an average target price of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.